Debut Biotech makes its entrance with a $22M series A for cell-free biomanufacturing facility

Debut Biotech wants to be the next big biomanufacturer, and the two-year-old startup thinks cell-free enzymes are the way forward. The company raised $22.6 million in series A funds Thursday to prove that out.